Patents Assigned to Merck
  • Conjugated polymers and blends containing carbazole, representation and use thereof
    Patent number: 8053547
    Abstract: The present invention relates to conjugated polymers comprising specific carbazole structural units. The materials according to the invention display steeper current-voltage curves and are therefore better suited to use in organic light-emitting diodes than are comparative polymers which do not contain these units.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: November 8, 2011
    Assignee: Merck Patent GmbH
    Inventors: Amir Parham, Aurelie Falcou, Susanne Heun, Heinrich Becker, Esther Breuning
  • Angiotensin II receptor antagonists
    Patent number: 8053455
    Abstract: A compound having the structure wherein R is an angiotensin receptor antagonist active group, Y is selected from the group consisting of and —C(R1H)OC(O)X((CR12R13)—(CHR10)m—(CH2)n—Zp—(CH2)q—(CHR11)r—(CR16R17))—R5;??2) Z is —O— or —(CR14R15)—; m, n, p, q, and r are independently selected from the group consisting of 0 and 1; X is —O— or —(CR18R19)—; R1 is selected from the group consisting of hydrogen, C1-4 alkyl, aryl and C1-4 alkylaryl; R5 is —O—N?N(O)—R3R4; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: November 8, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Christopher Franklin, Brent Whitehead
  • 9-(piperazinylalkyl) carbazoles as bax-modulators
    Patent number: 8053436
    Abstract: The present invention is related to piperazine derivatives of carbazole of formula (I) notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such piperazine derivatives of carbazole. Said piperazine derivatives of carbazole are efficient modulators, in particular efficient inhibitors, of the Bax function and/or activation. The present invention is furthermore related to novel piperazine derivatives of carbazole as well as methods of their preparation.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: November 8, 2011
    Assignee: Merck Serono SA
    Inventors: Serge Halazy, Dennis Church, Bruno Antonsson, Agnes Bombrun, Patrick Gerber, Jean-Claude Martinou
  • [(4-oxo-4H-chromen-3-yl)hydroxymethyl]- or [(4-oxo-4H-chromen-3-yl)methyl]phosphonic acid derivatives
    Patent number: 8052963
    Abstract: The present invention relates to compounds of the formula (I), where R1 to R3 each, independently of one another, denote H, hydroxyl or alkoxy having 1 to 8 C atoms, R4 denotes alkyl having 1 to 4 C atoms, H, hydroxyl or alkoxy having 1 to 8 C atoms, R5 denotes H or hydroxyl, and R6 denotes H or alkyl having 1 to 18 C atoms, or salts thereof, but where all R1 to R4 together cannot be equal to H, to compositions, and to the preparation and use thereof.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: November 8, 2011
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Christophe Carola, Herwig Buchholz
  • Pyridazinone derivatives
    Publication number: 20110269765
    Abstract: Compounds of the formula (I) in which D, R1, R2, R3, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: December 10, 2009
    Publication date: November 3, 2011
    Applicant: Merck Patent GmbH
    Inventors: Dieter Dorsch, Oliver Schadt, Frank Stieber, Andree Blaukat
  • COMPOUNDS FOR ELECTRONIC DEVICES
    Publication number: 20110266533
    Abstract: The present invention relates to compounds of the formula (1) and to the use thereof in organic electronic devices, and to organic electronic devices which comprise compounds of the formula (1), preferably as hole-transport materials and/or as emitting materials.
    Type: Application
    Filed: December 22, 2009
    Publication date: November 3, 2011
    Applicant: Merck Patent GmbH
    Inventors: Arne Buesing, Holger Heil, Philipp Stoessel, Amir Hossain Parham, Rocco Fortte, Jonas Valentin Kroeber
  • BENZOTHIAZOLONE DERIVATIVES
    Publication number: 20110269756
    Abstract: Compounds of the formula I, in which R1, R2, R3, R3?, R4, R4?, E, E?, E? and E?? have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Application
    Filed: December 8, 2009
    Publication date: November 3, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Frank Stieber, Oliver Schadt, Dieter Dorsch, Andree Blaukat
  • Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof
    Publication number: 20110269767
    Abstract: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.
    Type: Application
    Filed: December 4, 2009
    Publication date: November 3, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Axel Becker, Clemens Kuehn, Christoph Saal, Oliver Schadt, Dieter Dorsch, Heinz Hermann Bokel, Frank Stieber, Cristina Donini
  • NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS
    Publication number: 20110269758
    Abstract: Naphthyridinone derivative compounds that inhibit Aurora kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed Aurora kinases such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases.
    Type: Application
    Filed: June 29, 2009
    Publication date: November 3, 2011
    Applicant: MERCK PATENT GMBH
    Inventors: Yufang Xiao, Bayard R. Huck, Amanda E. Sutton, Xiaoling Chen, Srinivasa R. Karra, Andreas Goutopoulos
  • Method of producing functional protein domains
    Patent number: 8048645
    Abstract: The present invention provides a method of producing functional protein domains, which are fragments of primary translational products consisting of one or more distinct protein domains encoded by specific subsets of exonic sequences. The method is based on the integration, by a single homologous recombination event, of a regulatory unit into the eukaryotic gene coding for the primary translational product at the level of the intronic genomic region immediately adjacent to the exonic sequences which code for the functional protein domain.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: November 1, 2011
    Assignee: Merck Serono SA
    Inventors: Giampiero De Luca, Luca Falciola
  • Fluorosurfactants
    Patent number: 8049022
    Abstract: The present invention relates to fatty acid alkanolamides or polyolamides containing at least one group Y, where Y stands for CF3—(CH2)a—O—, SF5—, CF3—(CH2)a—S—, CF3CF2S—, [CF3—(CH2)a]2N— or [CF3—(CH2)a]NH—, where a stands for an integer selected from the range from 0 to 5, or formula (I), where Rf stands for CF3—(CH2)r—, CF3—(CH2)r—O—, CF3—(CH2)r—S—, CF3CF2—S—, SF5—(CH2)r— or [CF3—(CH2)r]2N—, [CF3—(CH2)r]NH— or (CF3)2N—(CH2)r—, B stands for a single bond, O, NH, NR, CH2, C(O)—O, C(O), S, CH2—O, O—C(O), N—C(O), C(O)—N, O—C(O)—N, N—C(O)—N, O—SO2 or SO2—O, R stands for alkyl having 1 to 4 C atoms, b stands for 0 or 1 and c stands for 0 or 1, q stands for 0 or 1, where at least one radical from b and q stands for 1, and r stands for 0, 1, 2, 3, 4 or 5, to processes for the preparation of these compounds, and to uses of these surface-active compounds.
    Type: Grant
    Filed: July 2, 2007
    Date of Patent: November 1, 2011
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Wolfgang Hierse, Nikolai (Mykola) Ignatyev, Martin Seidel, Elvira Montenegro, Peer Kirsch, Andreas Bathe
  • Insect poison allergens with reduced IgE reactivity and method for producing the same
    Patent number: 8048424
    Abstract: The invention relates to recombinant insect poison allergens and to a specific method for producing them. Said allergens can be varied according to whether they are produced using folds (conformations) that are identical or different to those that occur naturally. The proteins with folds that do not occur naturally have a reduced IgE reactivity or allergenity and can therefore be used as therapeutic agents in the immunotherapy of allergies.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: November 1, 2011
    Assignee: Merck Patent GmbH
    Inventors: Roland Suck, Oliver Cromwell, Helmut Fiebig
  • Use of liquid-crystal displays, and processes for the recycling thereof
    Patent number: 8048195
    Abstract: The present invention relates to the use of liquid-crystal displays (LCDs), and to processes for the recycling thereof. The processes according to the invention are characterised in that the LCDs are employed at least partly as replacement for other raw materials. In general, the LCDs are thermally treated here at a temperature in the range from 900 to 1700° C.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: November 1, 2011
    Assignee: Merck Patent GmbH
    Inventor: Roland Martin
  • POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL MEDIA AND LIQUID-CRYSTAL DISPLAYS
    Publication number: 20110261311
    Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays having a polymer-stabilised blue phase, and in LC media for LC displays of the PS or PSA (“polymer sustained” or “polymer sustained alignment”) type, and to LC media and LC displays comprising these compounds.
    Type: Application
    Filed: April 26, 2011
    Publication date: October 27, 2011
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Axel Jansen, Andreas Taugerbeck, Helmut Haensel, Achim Goetz
  • Novel pyrrolidone derivatives for use as MetAP-2 inhibitors
    Publication number: 20110263561
    Abstract: Compounds of the formula (I), in which R, X, Y, Z, R3 and R4 have the meanings indicated in claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
    Type: Application
    Filed: May 13, 2009
    Publication date: October 27, 2011
    Applicant: Merck Patent GmbH
    Inventors: Timo Heinrich, Mireille Krier, Thorsten Knoechel, Alfred Jonczyk, Frank Zenke, Holger Enderle
  • Polymerizable mesogenic cyclohexyl derivatives
    Patent number: 8043670
    Abstract: The invention relates to new polymerizable mesogenic or liquid crystalline compounds comprising a terminal cyclohexylphenyl group wherein the phenyl group has polar substituents, to polymerizable mesogenic or liquid crystalline mixtures and anisotropic polymers prepared thereof, and to the use of the new compounds and the mixtures and polymers prepared thereof in optical and electrooptical devices, adhesives, synthetic resins with anisotropic mechanical properties, cosmetics, diagnostics, liquid crystal pigments, decorative and security applications, nonlinear optics, optical information storage, electronic devices like organic field effect transistors (FET or OFET) or electroluminescent devices.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: October 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Stephan Derow
  • Liquid-crystalline medium and liquid crystal display
    Patent number: 8043671
    Abstract: Disclosed are a liquid-crystalline medium based on a mixture of dielectrically negative polar compounds of each of formulae I and II and the use thereof in an electro-optical display, particularly in a display with passive matrix addressing, based on a VA, ECB, PALC, FFS or IPS effect, and such displays.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: October 25, 2011
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Masahiro Iijima, Nobuo Kubo
  • Oligomers and polymers
    Patent number: 8043722
    Abstract: An optionally substituted oligomer or polymer comprising a repeat unit of formula (I); wherein each Ar1 and Ar3 is the same or different and independently represents an optionally substituted aryl or heteroaryl; n is at least 1; Ar2 represents an optionally substituted aryl or heteroaryl comprising a linking ring to which the two nitrogen atoms are both directly linked; and at least one of Ar2 and either or both of Ar1 is substituted with at least one substituent.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: October 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Paul Wallace, Carl Towns
  • Methods of using Fc-cytokine fusion proteins
    Patent number: 8043608
    Abstract: Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the surface of antigen presenting cells, thereby targeting the antigen to the antigen presenting cells in the mammal. In addition, disclosed is a family of adjuvants, for example, an Fc-adjuvant fusion protein, for use in combination with the Fc-antigen fusion proteins to enhance or modulate a particular immune response against the preselected antigen.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: October 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Stephen D. Gillies, Kin-Ming Lo, John S. Wesolowski, Jr.
  • White-emitting copolymers, representation, and use thereof
    Patent number: 8044217
    Abstract: The present invention relates to white-emitting copolymers which are obtained by a combination of blue-, green- and red-emitting repeating units. The copolymers of the invention display better film formation and an improved efficiency when used in polymeric organic light-emitting diodes compared to materials according to the prior art.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: October 25, 2011
    Assignee: Merck Patent GmbH
    Inventors: Aurelie Falcou, Arne Büsing, Susanne Heun, Jürgen Steiger, Anja Gerhard, Niels Schulte, Heinrich Becker